ReviewCureus2020
Ivabradine in Postural Orthostatic Tachycardia Syndrome: A Review of the Literature.
Review in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Use of Ivabradine in the Treatment of Patients with Postural Orthostatic Tachycardia Syndrome (POTS): A Systematic Review.Arquivos brasileiros de cardiologia · 2025Pooled it
- Postural orthostatic tachycardia syndrome after COVID-19 vaccination: A systematic review.BMC cardiovascular disorders · 2024Pooled it
- Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches.Annals of medicine · 2026Review
- A Case of Postural Orthostatic Tachycardia Syndrome in a 20-Year-Old Female Athlete: Review of Ivabradine Guidelines.JACC. Case reports · 2025Article
- Postural Orthostatic Tachycardia Syndrome Associated with COVID-19: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Article
- Insights into postural orthostatic tachycardia syndrome after COVID-19 in pediatric patients.World journal of pediatrics : WJP · 2024Article
- Microvascular Capillary and Precapillary Cardiovascular Disturbances Strongly Interact to Severely Affect Tissue Perfusion and Mitochondrial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Evolving from the Post COVID-19 Syndrome.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- Case report of long-term postural tachycardia syndrome in a patient after messenger RNA coronavirus disease-19 vaccination with mRNA-1273.European heart journal. Case reports · 2023Article
- Predicting Therapeutic Efficacy of Pharmacological Treatments in Children with Postural Orthostatic Tachycardia Syndrome: A Mini-Review.Children (Basel, Switzerland) · 2023Review
- Narrative Review of Postural Orthostatic Tachycardia Syndrome: Associated Conditions and Management Strategies.US cardiology · 2023Review
- Postural Orthostatic Tachycardia Syndrome in COVID-19: A Contemporary Review of Mechanisms, Clinical Course and Management.Vascular health and risk management · 2023Review
- Article
- What Do We Know Today about Long COVID? Nursing Care for a New Clinical Syndrome.International journal of environmental research and public health · 2022Article
- Reinnervation after cardioneuroablation: When on the run for best intraprocedural endpoints, be aware of possible ablation overdose.HeartRhythm case reports · 2022Article
- Postural orthostatic tachycardia syndrome following open thoracoabdominal aortic aneurysm repair.Journal of surgical case reports · 2021Article
- Recent updates on novel therapeutic targets of cardiovascular diseases.Molecular and cellular biochemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postural orthostatic tachycardia syndrome (POTS) is an autonomic disorder characterized by symptoms such as palpitations, dyspnea, chest discomfort, and lightheadedness affecting various systems. The pathophysiology of POTS is not completely understood due to a variety of symptoms showing that the disease is multifactorial. There is no approved uniform management strategy for POTS and hence, no drug has been approved by the United States (US) Food and Drug Administration (FDA) for it. Ivabradine is an FDA-approved drug for stable symptomatic heart failure (HF) and patients with an ejection fraction (EF) of ≤35%. Previous studies have depicted improvement in symptoms of POTS with the use of ivabradine. It is a selective inhibitor of funny sodium channels (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.